Table 4.
Multivariate analyses of leukemia-free survival, treatment-related mortality, and relapse in patients transplanted for first chronic phase
| Variable | n | Relative risk of death (95% CI) | P |
|---|---|---|---|
| Leukemia-free survival | |||
| Main effect | |||
| No imatinib | 657 | 1.00* | |
| Imatinib | 181 | 0.89 (0.68- 1.15) | .36† |
| Other significant covariates | |||
| GVHD prophylaxis | < .001‡ | ||
| MTX + CsA ± others | 537 | 1.00* | |
| T-cell depletion | 59 | 1.96 (1.40-2.76) | < .001 |
| FK506 + MTX ± others | 130 | 1.15 (0.86-1.55) | .340 |
| FK506 ± others | 19 | 2.60 (1.45-4.67) | .001 |
| CsA ± others | 93 | 1.58 (1.15-2.15) | .004 |
| Time from diagnosis to transplantation | |||
| ≤ 12 mo | 516 | 1.00 | |
| > 12 mo | 322 | 1.56 (1.27-1.93) | < .001† |
| Treatment-related mortality | |||
| Main effect | |||
| No imatinib | 657 | 1.00* | |
| Imatinib | 181 | 0.70 (0.49- 0.98) | .040† |
| Other significant covariates | |||
| Donor-recipient HLA match | < .001‡ | ||
| Matched sibling | 327 | 1.00* | |
| Well matched | 217 | 1.36 (0.96-1.93) | .080 |
| Partially matched | 160 | 1.74 (1.24-2.44) | .001 |
| Mismatch | 92 | 2.40 (1.65-3.47) | < .001 |
| Unknown | 42 | 1.78 (1.01-3.16) | .048 |
| Time from diagnosis to transplantation | |||
| ≤ 12 mo | 516 | 1.00 | |
| > 12 mo | 322 | 1.54 (1.20-1.99) | < .001† |
| Relapse§ | |||
| Main effect | |||
| No imatinib | 657 | 1.00* | |
| Imatinib | 181 | 1.54 (1.02-2.35) | .041† |
| Other significant covariates | |||
| GVHD prophylaxis | .004‡ | ||
| MTX + CsA ± others | 537 | 1.00* | |
| T-cell depletion | 59 | 2.67 (1.50-4.76) | < .001 |
| FK506 + MTX ± others | 130 | 1.08 (0.63-1.85) | .790 |
| FK506 ± others | 19 | 2.66 (1.10-6.46) | .031 |
| CsA ± others | 93 | 1.66 (0.94-2.95) | .083 |
CI indicates confidence interval.
*
Reference group.
†
One degree of freedom.
‡
Four degrees of freedom.
§
Stratified on conditioning regimen because of nonproportional hazards.